Overview of sample and patient characteristics for 444 tumors from 429 patients with mCRPC. Overview of sample and patient characteristics for 444 tumors.

Slides:

Advertisements

Similar presentations

Slide 1 Presented By Mark Stein at 2014 ASCO Annual Meeting.

Advertisements

Natural History of Prostate Cancer Local therapy Androgen deprivation therapy (ADT) Therapies after ADT Death ADT mCRPC post- docetaxel mCRPC symptomatic.

Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival in patients with metastatic CRPCa who have progressed.

Slides last updated: October There are two main types of lung cancer 1 1.Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review,

Case Study: Characterizing Diseased States from Expression/Regulation Data Tuck et al., BMC Bioinformatics, 2006.

Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.

Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.

R2 김재민 / Prof. 정재헌 Journal conference 1.

Main Figures and Tables

David Amar, Tom Hait, and Ron Shamir

Intermediate Atypical Carcinoma: Novel Histologic Subtype of mCRPC in Patients Resistant to Androgen Receptor Agonists CCO Independent Conference Highlights.

CCO Independent Conference Coverage

Lung squamous cell carcinoma

Finding the Right Fit: Personalizing Treatment in Metastatic Castration-Resistant Prostate Cancer.

Fig. 1 Selection of patients

Table 1 Baseline patient characteristics

Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer

RNA Sequencing Approaches to Identify Novel Biomarkers for Venous Thromboembolism (VTE) in Lung Cancer Tamara A. Sussman MD1, Mohamed Abazeed MD PhD1,

CD25 expression is associated with unfavorable clinical outcome.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Program Goals. The Clinical Impact of Second-Generation Antihormonal Therapy in the Treatment of mCRPC.

For the Urologist by the Urologist: Essential Concepts in Managing mCRPC.

Development of preclinical models for the guidance of precision medicine. Development of preclinical models for the guidance of precision medicine. A,

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Moving Prostate Cancer Care Forward: Putting Lessons From New Orleans and Chicago Into Practice.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)

Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p

AR signaling in CTCs from CRPC patients treated with abiraterone acetate. AR signaling in CTCs from CRPC patients treated with abiraterone acetate. A,

Volume 71, Issue 6, Pages (June 2017)

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Randomized phase III trial on Trabectedin (ET 743) vs clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers.

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers Carla Verri, MSc, Cristina Borzi, MSc, Todd Holscher,

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Published online September 20, 2017 by JAMA Surgery

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

PROSTATE CANCER CIRCULATING BIOMARKER CONSENSUS STATEMENT QUESTIONS

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

CT Characteristics and Pathologic Basis of Solitary Cystic Lung Cancer

Targeting the Androgen Pathway: Current Best Practice and Future Directions.

ONCOLOGYEDUCATION.COM ARTICLE SUMMARIES

Nat. Rev. Urol. doi: /nrurol

Pyoverdine production measured as RFUs standardized by OD significantly decreases with length of infection in years. Pyoverdine production measured as.

Integrative analysis incorporating histopathology, transcript-based assessment of AR signaling and NEPC score, TP53 and RB1 genomic status, and clinical.

Androgen receptor alterations and outcome.

Landscape of genomic alterations in 444 tumors from 429 patients with mCRPC. Landscape of genomic alterations in 444 tumors from 429 patients with mCRPC.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) for EGFR mutant lung adenocarcinoma.

Esteller, New England Journal of Medicine, 2008

Evaluating the Totality of Evidence

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

Overall Survival and Progression-free Survival

The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Progastrin expression in colonic tissues and Kaplan–Meier survival curves. Progastrin expression in colonic tissues and Kaplan–Meier survival curves. A,

Landscape of the TME in gastric cancer and characteristics of TME subtypes. Landscape of the TME in gastric cancer and characteristics of TME subtypes.

A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Somatic mutational rates and survival analysis of IBD-CRC.

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Association of overall survival and PAP-specific (A, B) and PA2024-specific (C, D) CTL activity at week 26 using categorical (tertile) analysis and continuous.

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Immune profiling of patient-derived organotypic tumor spheroids.

Uncovering the Right Sequence

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

CASP8 mutations are associated with fewer CNAs and RAS family mutations. CASP8 mutations are associated with fewer CNAs and RAS family mutations. A, number.

Presentation transcript:

Overview of sample and patient characteristics for 444 tumors from 429 patients with mCRPC. Overview of sample and patient characteristics for 444 tumors from 429 patients with mCRPC. (A) Site of mCRPC tumors profiled. (B) Histopathologic classification of profiled tumors. Tumors were classified by central review as adenocarcinoma, pure small-cell/neuroendocrine cancer, adenocarcinoma with neuroendocrine features (also included mixed acinar/neuroendocrine carcinoma), or could not be classified due to scant material or no tumor visible on the slides that were available for review despite successful sequencing. (C) Patient exposure status to next-generation AR signaling inhibitors (abiraterone acetate, enzalutamide, or ARN509) and to taxanes at the time of biopsy for the 444 profiled tumors. (D) Overall survival (OS) from the date of biopsy of the profiled tumor. OS was longer for tumors from ARSI- and taxane-naive patients compared with patients who had received an ARSI before the biopsy (P < 0.01, log-rank test). Survival was shortest when the patient had received both an ARSI and taxane chemotherapy at the time of biopsy. Wassim Abida et al. PNAS 2019;116:23:11428-11436 ©2019 by National Academy of Sciences